• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ontrak Announces 2023 First Quarter Financial Results

    5/10/23 4:05:00 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care
    Get the next $OTRK alert in real time by email

    Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the first quarter ended March 31, 2023.

    Management Commentary

    "We continue to be encouraged by market feedback to our new modularized WholeHealth set of solutions. This, coupled with improved cost controls and new expansion with existing customers, have us on good footing as we work hard to sign new customers and serve more members in need of our innovative behavioral health care offerings," commented Chief Executive Officer, Brandon LaVerne.

    First Quarter 2023 Financial Results Highlights

    • Revenue for the first quarter of 2023 was $2.5 million, representing a 52% decrease compared to the same period in 2022.
    • Operating loss for the first quarter of 2023 was $(7.2) million compared to an operating loss of $(13.1) million for the same period in 2022.
    • Adjusted EBITDA for the first quarter of 2023 was $(5.4) million compared to adjusted EBITDA of $(9.2) million for the same period in 2022.
    • Net loss for first quarter of 2023 was $(8.4) million, or a $(0.38) diluted net loss per common share (after deduction for undeclared preferred stock dividends), compared to net loss of $(14.6) million, or a $(0.81) diluted net loss per common share (after deduction for declared and undeclared preferred stock dividends) for the same period in 2022.
    • Non-GAAP net loss for first quarter of 2023 was $(7.7) million, or a $(0.35) non-GAAP diluted net loss per common share (after deduction for declared and undeclared preferred stock dividends), compared to non-GAAP net loss of $(11.7) million, or a $(0.67) non-GAAP diluted net loss per common share (after deduction for declared and undeclared preferred stock dividends) for the same period in 2022.

    Adjusted EBITDA, non-GAAP net loss and non-GAAP diluted net loss per common share are non-GAAP financial measures. See our description and reconciliation of such non-GAAP measures at the end of this release.

    First Quarter 2023 and Recent Operating Highlights

    • Total enrolled members numbered 1,526 at the end of Q1 2023.
    • In March 2023, as part of the Company's continued cost saving measures and to reduce its operating costs and to help align with its previously stated strategic initiatives, the Company implemented additional headcount reductions wherein approximately 19% of the Company's employee positions were eliminated, which is expected to result in a reduction of approximately $2.7 million of annual compensation costs.
    • On March 2, 2023, Terren S. Peizer resigned as a member of the Board of Directors, as Chairman of the Board, as Executive Chairman, and as Chief Executive Officer of the Company, effective immediately. Mr. Peizer explained that his resignation was for the good of the Company and to minimize any distraction from the important work that the Company does. The Company's Board of Directors appointed Brandon H. LaVerne as Interim Chief Executive Officer and Mary Louise Osborne as President. Mr. LaVerne continues to serve as the Company's Chief Operating Officer and Ms. Osbourne continues to serve as the Company's Chief Commercial Officer.
    • On March 9, 2023, the Company announced its partnership with Lyssn, an innovative software platform that uses AI and natural language processing to enhance communication and outcomes between healthcare professionals and their members. The partnership will provide the Company's care coaches real-time analysis and feedback on the fidelity of Motivational Interviewing (MI) during coaching calls with members.
    • On March 28, 2023, the Company announced with MyndYou, creators of an AI-powered Virtual Care Coordinator, that Ontrak will use MyndYou's MyEleanor, an AI-powered conversational platform, to engage with members, triage needs, and address issues pertaining to behavioral, medical, or social care needs. The announcement comes after a successful pilot program of Ontrak using MyEleanor in which approximately 38% of members contacted were re-engaged with Ontrak's evidence-based behavioral health coaching services.

    Financial Outlook

    The following outlook is based on information available as of the date of this press release and is subject to change in the future.

    For the year ending December 31, 2023, the Company estimates revenue in the range of $12 to $14 million. The foregoing estimate is based on existing and currently planned enrollment launches, currently anticipated program expansions with current health plan partners, current expectations with the Company's existing customers regarding outreach pool, budget considerations and timing of expansions.

    Conference Call & Webcast Details

    The Company will host a conference call/webcast today at 4:30 pm ET/1:30 pm PT. Investors, analysts, employees and the general public can access the call by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call.

    A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

    About Ontrak, Inc.

    Ontrak, Inc. is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company's integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.

    Learn more at www.ontrakhealth.com

    Forward-Looking Statements

    This press release contains "forward-looking" statements that are based on the Company's beliefs and assumptions and on information currently available to the Company on the date of this press release and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "may," "will," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plan," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words. Forward-looking statements may include, but are not limited to, the Company's belief that its strategy will accelerate the Company's return to growth, maximize the Company's differentiated platform, and strengthen the Company's position, the Company's expectations regarding reductions in costs resulting from its cost saving measures, and the Company's estimated revenue for 2023. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements, including, without limitation, risks related to: the Company's ability to successfully execute on its strategy and business plan; the Company's ability to increase its revenue and efficiently manage expenses and achieve profitability; the Company's high customer concentration and the ability of its customers to terminate their contracts for convenience; the adequacy of the Company's existing cash resources and anticipated capital commitments and future cash requirements to enable the Company to continue as a going concern; the Company's ability to raise additional capital when needed; difficulty enrolling new members and maintaining existing members in the Company's programs; the effectiveness of the Company's treatment programs; lower than anticipated eligible members under the Company's contracts; the Company's dependence on key personnel and the Company's ability to recruit and retain key personnel; the Company's ability to maintain the listing of its stock on Nasdaq; the outcomes of ongoing legal proceedings brought by the U.S. Department of Justice and the Securities and Exchange Commission against the Company's largest stockholder and former Chief Executive Officer and Chairman, and whether governmental authorities will institute separate investigations or proceedings against the Company and/or its current or former executives and/or directors; substantial regulation in the health care industry; changes in regulations or issuance of new regulations or interpretations; the Company's limited operating history; difficulty in developing, exploiting and protecting proprietary technologies; business disruption and related risks resulting from the COVID-19; general economic conditions, nationally and globally, and their effect on the market for our service; intense competition and competitive pressures and trends in the Company's industry and the Company's ability to successfully compete; changes in laws, regulations, or policies; and risks related to the Company's ability to realize the potential benefits of and to effectively integrate acquisitions. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Forward-looking statements are current only as of the date they are made and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Non-GAAP Financial Measures

    To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles, or GAAP, the Company has provided in this press release and the quarterly conference call held on the date hereof certain non-GAAP financial measures. The non-GAAP financial measures presented include EBITDA, Adjusted EBITDA, Non-GAAP net loss, and Non-GAAP net loss per common share, which are not U.S. GAAP financial measures. We believe that the presentation of these financial measures enhances an investor's understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

    EBITDA consists of net loss before interest, taxes, depreciation and amortization expenses. Adjusted EBITDA consists of net loss before interest, taxes, depreciation, amortization, stock-based compensation, restructuring, severance and related costs, acquisition related costs, and loss (gain) on change in fair value of warrant liability and contingent liability. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.

    Non-GAAP net loss consists of net loss adjusted for stock-based compensation, write-off of debt discount costs, restructuring, severance and related costs, acquisition related costs and loss (gain) on change in fair value of warrant liabilities and contingent liability. Non-GAAP net loss per common share consists of loss per share adjusted for non-GAAP net loss attributable to common stockholders. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.

    We believe the above non-GAAP financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term EBITDA, Adjusted EBITDA, Non-GAAP net loss and Non-GAAP net loss per common share may vary from that of others in our industry. None of EBITDA, Adjusted EBITDA, Non-GAAP net loss or Non-GAAP net loss per common share should be considered as an alternative to net loss before taxes, net loss, net loss per common share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.

    See the Reconciliation of Non-GAAP Measures table at the end of this press release for a reconciliation of the Non-GAAP financial measures to U.S. GAAP financial measures.

    ONTRAK, INC.

    Consolidated Statements of Operations

    (in thousands, except per share data)

    (unaudited)

     

     

     

     

     

    Three Months Ended

    March 31,

     

     

    2023

     

    2022

    Revenue

     

    $

    2,529

     

     

    $

    5,258

     

    Cost of revenue

     

     

    847

     

     

     

    2,846

     

    Gross profit

     

     

    1,682

     

     

     

    2,412

     

     

     

     

     

     

    Operating expenses:

     

     

     

     

    Research and development

     

     

    1,644

     

     

     

    3,428

     

    Sales and marketing

     

     

    990

     

     

     

    1,436

     

    General and administrative

     

     

    5,818

     

     

     

    10,693

     

    Restructuring, severance and related charges

     

     

    457

     

     

     

    —

     

    Total operating expenses

     

     

    8,909

     

     

     

    15,557

     

    Operating loss

     

     

    (7,227

    )

     

     

    (13,145

    )

     

     

     

     

     

    Other income, net

     

     

    291

     

     

     

    —

     

    Interest expense, net

     

     

    (1,394

    )

     

     

    (1,400

    )

    Loss before income taxes

     

     

    (8,330

    )

     

     

    (14,545

    )

    Income tax expense

     

     

    (20

    )

     

     

    (100

    )

    Net loss

     

     

    (8,350

    )

     

     

    (14,645

    )

    Dividends on preferred stock - declared and undeclared

     

     

    (2,239

    )

     

     

    (2,239

    )

    Net loss attributable to common stockholders

     

    $

    (10,589

    )

     

    $

    (16,884

    )

     

     

     

     

     

    Net loss per common share, basic and diluted

     

    $

    (0.38

    )

     

    $

    (0.81

    )

     

     

     

     

     

    Weighted-average common shares outstanding, basic and diluted

     

     

    28,115

     

     

     

    20,723

     

    ONTRAK, INC.

    Consolidated Balance Sheets

    (in thousands, except share and per share data)

     

     

     

     

     

     

     

    March 31,

     

    December 31,

     

     

    2023

     

    2022

    Assets

    (unaudited)

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    7,393

     

     

    $

    5,032

     

    Restricted cash - current

     

    4,681

     

     

     

    4,477

     

    Receivables, net

     

    695

     

     

     

    973

     

    Unbilled receivables

     

    236

     

     

     

    453

     

    Deferred costs - current

     

    160

     

     

     

    156

     

    Prepaid expenses and other current assets

     

    2,288

     

     

     

    3,168

     

    Total current assets

     

    15,453

     

     

     

    14,259

     

    Long-term assets:

     

     

     

    Property and equipment, net

     

    2,241

     

     

     

    2,498

     

    Restricted cash - long-term

     

    —

     

     

     

    204

     

    Goodwill

     

    5,713

     

     

     

    5,713

     

    Intangible assets, net

     

    820

     

     

     

    1,125

     

    Other assets

     

    381

     

     

     

    1,326

     

    Operating lease right-of-use assets

     

    238

     

     

     

    632

     

    Total assets

    $

    24,846

     

     

    $

    25,757

     

     

     

     

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    1,706

     

     

    $

    1,927

     

    Accrued compensation and benefits

     

    2,106

     

     

     

    1,987

     

    Deferred revenue

     

    309

     

     

     

    326

     

    Current portion of operating lease liabilities

     

    60

     

     

     

    653

     

    Other accrued liabilities

     

    4,032

     

     

     

    4,576

     

    Total current liabilities

     

    8,213

     

     

    9,469

     

    Long-term liabilities:

     

     

     

    Long-term debt, net

     

    9,804

     

     

     

    10,065

     

    Long-term operating lease liabilities

     

    209

     

     

     

    546

     

    Total liabilities

     

    18,226

     

    20,080

     

    Commitments and contingencies

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

    Preferred stock, $0.0001 par value; 50,000,000 shares authorized; 3,770,265 shares issued and outstanding at each of March 31, 2023 and December 31, 2022

     

    —

     

     

     

    —

     

    Common stock, $0.0001 par value, 500,000,000 shares authorized; 29,320,248 and

    27,167,479 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively

     

    3

     

     

     

    3

     

    Additional paid-in capital

     

    457,708

     

     

     

    448,415

     

    Accumulated deficit

     

    (451,091

    )

     

     

    (442,741

    )

    Total stockholders' equity

     

    6,620

     

     

     

    5,677

     

    Total liabilities and stockholders' equity

    $

    24,846

     

     

    $

    25,757

     

     

     

     

     

    ONTRAK, INC.

    Consolidated Statements of Cash Flows

    (in thousands, unaudited)

     

     

     

     

     

    For the Three Months Ended

    March 31,

     

     

    2023

     

    2022

    Cash flows from operating activities

     

     

     

    Net loss

    $

    (8,350

    )

     

    $

    (14,645

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Stock-based compensation expense

     

    651

     

     

     

    2,911

     

    Paid-in-kind interest expense

     

    848

     

     

     

    —

     

    Gain on termination of operating lease

     

    (471

    )

     

     

    —

     

    Depreciation expense

     

    295

     

     

     

    651

     

    Amortization expense

     

    912

     

     

     

    637

     

    Change in fair value of warrant liability

     

    19

     

     

     

    —

     

    401(k) employer match in common shares

     

    —

     

     

     

    202

     

    Common stock issued for consulting services

     

    —

     

     

     

    102

     

    Changes in operating assets and liabilities:

     

     

     

    Receivables

     

    278

     

     

     

    163

     

    Unbilled receivables

     

    217

     

     

     

    (933

    )

    Prepaid expenses and other current assets

     

    836

     

     

     

    351

     

    Accounts payable

     

    (258

    )

     

     

    789

     

    Deferred revenue

     

    (18

    )

     

     

    47

     

    Leases liabilities

     

    (118

    )

     

     

    124

     

    Other accrued liabilities

     

    206

     

     

     

    (890

    )

    Net cash used in operating activities

     

    (4,953

    )

     

     

    (10,491

    )

     

     

     

     

    Cash flows from investing activities

     

     

     

    Purchase of property and equipment

     

    (25

    )

     

     

    (255

    )

    Net cash used in investing activities

     

    (25

    )

     

     

    (255

    )

     

     

     

     

    Cash flows from financing activities

     

     

     

    Proceeds from Keep Well Notes

     

    8,000

     

     

     

    —

     

    Dividends paid

     

    —

     

     

     

    (2,239

    )

    Repayments of 2024 Notes

     

    —

     

     

     

    (19,994

    )

    Finance lease obligations

     

    (50

    )

     

     

    (84

    )

    Financed insurance premium payments

     

    (611

    )

     

     

    (750

    )

    Payment of taxes related to net-settled stock awards

     

    —

     

     

     

    (2

    )

    Net cash provided by (used in) financing activities

     

    7,339

     

     

     

    (23,069

    )

    Net change in cash and restricted cash

     

    2,361

     

     

     

    (33,815

    )

    Cash and restricted cash at beginning of period

     

    9,713

     

     

     

    65,946

     

    Cash and restricted cash at end of period

    $

    12,074

     

     

    $

    32,131

     

     

     

     

     

    Supplemental disclosure of cash flow information:

     

     

     

    Interest paid

    $

    27

     

     

    $

    1,181

     

    Income taxes refunded, net

     

    (72

    )

     

     

    —

     

    Non-cash financing and investing activities:

     

     

     

    Warrants issued in connection with Keep Well Notes

    $

    10,797

     

     

    $

    —

     

    Finance lease and accrued purchases of property and equipment

     

    44

     

     

     

    187

     

    Common stock issued to settle contingent consideration

     

    —

     

     

     

    213

     

    ONTRAK, INC.

    Reconciliation of Non-GAAP Measures

    (in thousands, except per share data)

     

     

     

     

     

    Reconciliation of Operating Loss to EBITDA and Adjusted EBITDA

     

     

     

    Three Months Ended

    March 31,

     

     

    2023

     

    2022

    Operating loss

     

    $

    (7,227

    )

     

    $

    (13,145

    )

    Depreciation expense

     

     

    295

     

     

     

    651

     

    Amortization expense (1)

     

     

    391

     

     

     

    395

     

    EBITDA

     

     

    (6,541

    )

     

     

    (12,099

    )

    Stock-based compensation expense

     

     

    651

     

     

     

    2,911

     

    Restructuring, severance and related costs (2)

     

     

    457

     

     

     

    —

     

    Adjusted EBITDA

     

    $

    (5,433

    )

     

    $

    (9,188

    )

    Reconciliation of Net Loss to Non-GAAP Net Loss; and Net Loss per Common Share to Non-GAAP Net Loss per Common Share

     

     

     

    Three Months Ended

    March 31,

     

     

    2023

     

    2022

    Net loss

     

    $

    (8,350

    )

     

    $

    (14,645

    )

    Stock-based compensation expense

     

     

    651

     

     

     

    2,911

     

    Restructuring, severance and related costs (2)

     

     

    457

     

     

     

    —

     

    Loss on change in fair value of warrant liability

     

     

    19

     

     

     

    —

     

    Gain on termination of operating lease (3)

     

     

    (471

    )

     

     

    —

     

    Non-GAAP net loss

     

     

    (7,694

    )

     

     

    (11,734

    )

    Dividends on preferred stock - declared and undeclared

     

     

    (2,239

    )

     

     

    (2,239

    )

    Non-GAAP net loss attributable to common stockholders

     

    $

    (9,933

    )

     

    $

    (13,973

    )

     

     

     

     

     

    Net loss per common share - basic and diluted

     

    $

    (0.38

    )

     

    $

    (0.81

    )

    Non-GAAP net loss per common share - basic and diluted

     

     

    (0.35

    )

     

     

    (0.67

    )

    Weighted-average common shares outstanding - basic and diluted

     

     

    28,115

     

     

     

    20,723

     

    _______________________

    (1)

    Relates to operating and financing ROU assets and acquired intangible assets.

    (2)

    Includes one-time severance and related benefit costs related to a reduction in workforce announced in March 2023 as part of Company's continued cost savings measure.

    (3)

    Represents gain realized on derecognition of ROU operating asset and related lease liability due to early termination of the lease of the office space located in Santa Monica, CA.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005332/en/

    Get the next $OTRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTRK

    DatePrice TargetRatingAnalyst
    12/5/2023$4.00Buy
    ROTH MKM
    3/9/2022$13.00 → $2.50Hold
    Canaccord Genuity
    3/9/2022$11.00 → $2.00Sector Perform
    RBC Capital
    8/20/2021$35.00 → $9.00Market Perform → Underperform
    Cowen & Co.
    8/20/2021$15.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $OTRK
    SEC Filings

    View All

    Ontrak Inc. filed SEC Form 8-K: Other Events, Leadership Update

    8-K - Ontrak, Inc. (0001136174) (Filer)

    8/28/25 4:32:50 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    SEC Form NT 10-Q filed by Ontrak Inc.

    NT 10-Q - Ontrak, Inc. (0001136174) (Filer)

    8/15/25 6:36:38 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Ontrak Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Ontrak, Inc. (0001136174) (Filer)

    8/13/25 4:13:55 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    $OTRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Electronic Data Interchange Market Size to Grow USD 74.36 billion by 2031, Rising Digital Transformation Across Various Industries Propels | The Insight Partners

    NEW YORK, July 21, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the electronic data interchange (EDI) market is observing significant growth owing to the rising digital transformation across various industries and the growing adoption of EDI in small and medium enterprises. The electronic data interchange market was valued at US$34.02 billion in 2024 and is projected to reach US$74.36 billion by 2031; it is expected to register a CAGR of 11.9% during 2025-2031.  The electronic data interchange market comprises an array of components a

    7/21/25 11:30:00 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Ontrak Health Announces Pricing of $4 Million Public Offering

    Ontrak, Inc. (NASDAQ:OTRK), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, today announced the pricing of a public offering of 6,666,667 shares of its common stock (or pre-funded warrants in lieu thereof) and 26,666,668 warrants to purchase up to 26,666,668 shares of its common stock at a combined public offering price of $0.60 per share of common stock and accompanying warrants or at a combined public offering price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-fund

    6/27/25 8:30:00 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Ontrak Health Announces Expansion of Engage Solution for Sentara Health Plans Self-funded Employer Customers

    Ontrak, Inc. (NASDAQ:OTRK), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, today announced an expanded partnership with Sentara Health Plans to offer Ontrak's Engage Solution to employer sponsored customers in the Commonwealth of Virginia. Sentara Health Plans is the health plan division of Sentara Health, an integrated, not-for-profit health care delivery system that provides health plan coverage to one million members in Virginia and Florida. Sentara offers programs to support members with chronic illnesses, customized wellness programs, and integrated clinical and behavioral health services—all to help members improve their heal

    6/24/25 8:00:00 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    $OTRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Peizer Terren S exercised 500,000 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - Ontrak, Inc. (0001136174) (Issuer)

    6/24/25 6:32:14 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 4 filed by Large owner Peizer Terren S

    4 - Ontrak, Inc. (0001136174) (Issuer)

    6/23/25 8:06:38 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Chief Financial Officer Park James J converted options into 4 shares and covered exercise/tax liability with 1 shares, increasing direct ownership by 33% to 12 units (SEC Form 4)

    4 - Ontrak, Inc. (0001136174) (Issuer)

    6/17/25 5:33:52 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    $OTRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ontrak with a new price target

    ROTH MKM initiated coverage of Ontrak with a rating of Buy and set a new price target of $4.00

    12/5/23 8:03:01 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Canaccord Genuity reiterated coverage on Ontrak with a new price target

    Canaccord Genuity reiterated coverage of Ontrak with a rating of Hold and set a new price target of $2.50 from $13.00 previously

    3/9/22 9:09:19 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    RBC Capital reiterated coverage on Ontrak with a new price target

    RBC Capital reiterated coverage of Ontrak with a rating of Sector Perform and set a new price target of $2.00 from $11.00 previously

    3/9/22 7:43:55 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    $OTRK
    Leadership Updates

    Live Leadership Updates

    View All

    Ontrak Names James Messina to its Board of Directors

    Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of James Messina as a non-Executive Director to its board. Mr. Messina is a Co-Founder and General Partner of Seattle Hill Ventures and x4 Capital Partners, which invest in, and support, startup ventures by providing business development, marketing, operating and technology support. Previously, Mr. Messina was the Executive Vice President and Chief Operating Officer for Premera Blue Cross ("Premera"). He was responsible for effectively servicing the needs of Premera's customers with oversight of all operational functions, from customer serv

    8/30/22 8:00:00 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Ontrak Names Dr. Robert Accordino Chief Medical Officer

    Mental Healthcare Leader and Harvard Medical School Faculty Member Joins Ontrak Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Dr. Robert Accordino as Ontrak's Chief Medical Officer, effective September 27, 2021. Dr. Accordino joins Ontrak from Quartet Health where he served as the company's most senior clinician and Chief Mental Health Officer. He practices psychiatry and is on the faculty of Harvard Medical School and Massachusetts General Hospital. Dr. Accordino will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "Dr. Accordino's reputation in

    9/9/21 8:00:00 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Arik Hill Joins Ontrak as Chief Information Officer

    Former Accenture and KPMG Healthcare Expert Brings Proven Leadership Experience In Behavioral Health Digital Transformation Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Arik Hill as Ontrak's first Chief Information Officer, effective August 30, 2021. Mr. Hill will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "As Chief Information Officer at The New York Foundling, a fast growing organization that collaborates with over 250,000 behavioral healthcare partners across the country, Arik led the development of digital platforms and applications th

    8/12/21 8:00:00 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    $OTRK
    Financials

    Live finance-specific insights

    View All

    Ontrak Health Announces 2025 First Quarter Financial Results

    Q1 Revenue of $2.0 million, down 25% year over year Q1 Operating loss of $(5.9) million, a 37% increase year over year Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) Company to Host Conference Call at 4:30 pm ET Today Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025. Manageme

    5/20/25 4:05:00 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Ontrak Health to Report 2025 First Quarter Financial Results on May 20, 2025

    Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the first quarter 2025 on Tuesday, May 20, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events . Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before

    5/19/25 4:30:00 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Ontrak Health to Report 2024 Fourth Quarter Financial Results on April 14, 2025

    Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the fourth quarter 2024 on Monday, April 14, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/delivering-a-healthier-future-for-all/presentations-events/. Participants interested in dialing in to the conference call are requested to register a day in advance or

    4/10/25 4:05:00 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    $OTRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

    SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

    10/3/24 6:37:08 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

    SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

    8/30/24 5:15:15 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care